The in vitro response of peripheral blood mononuclear cells (PBMCs) to the suppressive effects of calcineurin inhibitors is known to correlate with the clinical efficacy of drugs used in renal transplantations. The present study was conducted to examine the differences of PBMC responses to calcineurin inhibitors between chronic renal failure (CRF) patients awaiting renal transplantation and cirrhosis patients awaiting liver transplantation. The study included 99 CRF patients awaiting renal transplantation and 27 cirrhosis patients awaiting liver transplantation. Twenty milliliters of venous blood was taken 1-7 days before transplantation. The in vitro drug concentrations giving 50% inhibition of PBMC blastogenesis stimulated with concanavalin A (IC 50 s) were calculated. The suppressive effects of tacrolimus against PBMC blastogenesis were more than 10-100 times stronger than those of cyclosporine. The median IC 50 value for cyclosporine against the CRF PBMCs was not significantly different from the median IC 50 value against the cirrhosis PBMCs. In contrast, tacrolimus sensitivity in cirrhosis PBMCs is approximately seven times higher than that in CRF PBMCs. The median IC 50 value for tacrolimus against cirrhosis PBMCs was significantly lower and therefore the effect was stronger in comparison to the CRF PBMCs (p < 0.001). These data suggest that the PBMCs of cirrhosis patients, in comparison to those of CRF patients, are highly sensitive to the suppressive effect of tacrolimus. However, PBMC sensitivity to cyclosporine was not significantly different between the CRF and cirrhosis patients. These observations raise the possibility that treatment with tacrolimus, rather than cyclosporine, may therefore be a better choice to reduce the risks of allograft rejection in liver transplantation.
INTRODUCTION
cacy of calcineurin inhibitors in individual patients is the cellular pharmacodynamics of drugs using the patients' peripheral blood mononuclear cells (PBMCs) (13-17). Immunosuppressive drugs, including calcineurin inhibitors, are indispensable in the treatment of organ trans-
The in vitro response of PBMCs to the suppressive effects of glucocorticoids and calcineurin inhibitors is cor-plantations (2, 5, 19, 21, (25) (26) (27) 31) . Therefore, the clinical outcome of organ transplant recipients is affected by related with the clinical efficacy of the drugs in treating renal transplantation (6, 14, 15, 17, 30) , asthma (8) , mini-successful immunosuppressive drug therapy. However, variations in the clinical efficacy of immunosuppressive mal change nephrotic syndrome (16) , psoriasis (15, 17) , rheumatoid arthritis (18) , and ulcerative colitis (11). Cal-drugs in individual patients has been observed and patients with poor responses to their drug therapy have cineurin inhibitors, cyclosporine and tacrolimus, are the key drugs for successful organ transplantation; however, required long-term or relatively high doses and thus have experienced rejection episodes and/or serious side there is limited evidence available to justify the selection of either cyclosporine or tacrolimus in renal and liver effects (4, 5, 17, 21, 25, 27, 31) .
One of the attractive ways to predict the clinical effi-transplantations. The alternative use of these drugs 640 KIHARA ET AL.
based on individual PBMC sensitivity before transplan-transplantation and cirrhosis patients awaiting liver transplantation. tation should thus be considered for the improvement of graft outcome in these recipients. In addition, the best calcineurin inhibitor for the treatment of renal and liver MATERIALS AND METHODS transplantations, respectively, on the basis of recipient Subjects drug sensitivity has not been considered. However, no comparative study has been carried out for PBMC sensi-
The present study was approved by the Ethical Committees of Tokyo Medical University and Tokyo Univer-tivities to calcineurin inhibitors between renal transplant recipients and liver transplant recipients. sity of Pharmacy and Life Sciences and informed consent was obtained from all patients. The study included The present study was thus conducted to examine the differences in the in vitro response of PBMCs to calcine-99 CRF patients awaiting kidney transplantation (51 male and 48 female; 55.2 ± 10.1 years of age) and 27 urin inhibitors between CRF patients awaiting renal cirrhosis patients awaiting liver transplantation (11 male with hepatitis C virus (HCV) infection (11 of which had hepatocellular carcinoma), five with hepatitis B virus and 16 female; 53.1 ± 8.2 years of age). Liver or kidney transplantation was applicable to all of these patients, (HBV) infection (three of which had hepatocellular carcinoma), four with primary biliary cirrhosis, two with respectively, and blood sampling was carried out before transplantation. None of the patients included in this autoimmune hepatitis, and one unknown. The Child-Pugh classification of these patients was grade A (n = study had a history of taking immunosuppressive drugs. Cirrhosis patients examined in this study included 15 4) , grade B (n = 9), and grade C (n = 14), respectively. All other reagents were of the best available grade. patients awaiting liver transplantation. Fisher's exact probability tests were used to compare the proportion of males and females in the two subject groups. IC 50 values for immunosuppressive drugs are reported as the mean Cell Culture and Evaluation (SD) or median (range). For the comparison of IC 50 valof Immunosuppressant Pharmacodynamics ues between PBMCs of CRF patients and those of cir-Twenty milliliters of venous blood was taken from rhosis patients, the data were first checked with a varipatients 1-7 days before transplantation between 0930 ance analysis. Subsequently, the data were analyzed and 1100 h in the morning and heparinized. This 20-ml with Mann-Whitney's U-test. Correlations between the sample size was the smallest possible to carry out drug IC 50 values of two calcineurin inhibitors were analyzed sensitivity tests for two calcineurin inhibitors, but occawith Pearson's correlation coefficient test. These analysionally two of these agents could not be tested from ses were performed with Statview (10). In each case, each subject. The heparinized blood was loaded on 3 ml two-sided values of p < 0.05 were considered to be sigof Ficoll-Hypaque (Nakarai Co., Japan), centrifuged at nificant. 1300 × g for 20 min, and PBMCs were separated as de-RESULTS scribed previously. The cells were washed and resuspended in an RPMI-1640 medium containing 10% fetal Typical dose-response curves of calcineurin inhibicalf serum, 100,000 IU/L penicillin, and 100 mg/L tors against mitogen-induced blastogenesis of PBMCs streptomycin to a final density of 1 × 10 6 cells/ml. Conobtained from one CRF patient and one cirrhosis patient canavalin A, as the mitogen, was added to each well to are presented in Figure 1 . The suppressive effects of taa final concentration of 5.0 µg/ml. Subsequently, 4 µl crolimus were more than 10-100 times stronger than of an ethanol solution containing cyclosporine or tacrolithose of cyclosporine. In addition, the dose-response mus were added to give final agent concentrations of curve of tacrolimus against the PBMCs of the cirrhosis 0.001-10,000 ng/ml. Four microliters of ethanol was patients was shifted to low concentration ranges, in comadded to the control wells. The plate was incubated for parison to the dose-response curve against PBMCs of 96 h in 5% CO 2 /air at 37°C. The cells were pulsed with the CRF patients.
KBq/well of [ 3 H]thymidine for the last 16 h of in-
Next, the IC 50 values of the PBMCs of cyclosporine cubation and then collected on a glass-fiber filter paper were compared between the PBMCs of the 93 CRF pausing a multiharvester device and dried. The radioactivtients and those of the 26 cirrhosis patients. The IC 50 ity retained on the filter was further processed for liquid values for tacrolimus were also compared between the scintillation counting. The mean of the counts for a du-PBMCs of 39 CRF patients and those of 19 cirrhosis plicate or triplicate of each sample was determined. A patients. The IC 50 values for cyclosporine against the PBMC stimulation index was calculated from the forblastogenesis of PBMCs from the CRF patients showed mula: [ 3 H]thymidine incorporated in the presence of wide individual variations and were not significantly difconcanavalin A (dpm)/ [ 3 H]thymidine incorporated in ferent from those against the PBMCs of the cirrhosis the absence of stimulant (dpm). Agent concentrations patients (p = 0.771) ( Fig. 2a ). The tacrolimus IC 50 values that would give 50% PBMC blastogenesis inhibition against the blastogenesis of both the CRF patients' (IC 50 ) were determined from the dose-response curve.
PBMCs and cirrhosis patients' PBMCs also showed large individual variations (Fig. 2b) . However, the me-Materials dian IC 50 value for tacrolimus against the blastogenesis of cirrhosis PBMCs was significantly lower than that RPMI-1640 medium and fetal calf serum were purchased from Gibco Co. (USA). Concanavalin A was ob-against the blastogenesis of the CRF PBMCs (p < 0.001) (Fig. 2b) . The means (SD) and medians (range) of these tained from Seikagaku Kogyo Co. (Japan). Cyclosporine calcineurin inhibitors are presented in Table 1 . The dif-cyclosporine and tacrolimus in both CRF patients (n = 33) and cirrhosis patients (n = 18) was examined. The ference in the median cyclosporine IC 50 value between the CRF PBMCs and cirrhosis PBMCs was small and IC 50 values for cyclosporine correlated significantly with the IC 50 values for tacrolimus ( Fig. 3a, b ). However, this not statistically significant, whereas the difference in the tacrolimus IC 50 values between these patient groups correlation in the CRF PBMCs (p = 0.024) was weaker than that in the cirrhosis PBMCs (p < 0.001). In the case came to approximately seven times or more.
In addition, the relationship of IC 50 values between of CRF and cirrhosis, some of the patients (e.g., num-bered patients in Fig. 3 ) deviated largely from each cor-paid to the overdosing of the drugs for the prevention of infectious diseases. Moreover, immunosuppressive drugs, relation curve to either the ordinate or the horizontal line.
including calcineurin inhibitors, are generally expensive and an individualized dose-management of these drugs DISCUSSION based on the drug sensitivity of PBMCs is also encouraging from this point of view. No significant difference This study compared the median IC 50 values of cyclosporine and tacrolimus between cirrhosis PBMCs in the incidence of recurrence of hepatitis from C hepatitis virus infection has been reported between the liver and CRF PBMCs and showed the tacrolimus sensitivity in the cirrhosis PBMCs to be approximately seven times transplant recipients treated with tacrolimus and those treated with cyclosporine (3, 12) . The preferable clinical higher than that in CRF PBMCs. However, PBMC sensitivity to cyclosporine was not significantly different course of liver transplant recipients treated with either cyclosporine or tacrolimus is controversial (9, 20, 23) , but between the CRF and cirrhosis patients. These findings suggest that the PBMCs of cirrhosis patients, in compar-a recent report by O'Grady et al. showed significant improvement of graft survival in tacrolimus-treated recipi-ison to those of CRF patients, are vulnerable to the immunosuppressive effects of tacrolimus in vitro. There-ents, rather than cyclosporine-treated recipients (23) . The molecular basis for the difference in PBMC sen-fore, the results obtained in the PBMCs of cirrhosis patients are different from those obtained from the sitivity to tacrolimus between CRF and cirrhosis was not clarified in the present study. However, an interesting PBMCs of CRF patients, in regard to tacrolimus sensitivity.
observation was that anti-FKBP12 autoantibodies detected in liver transplant recipients may modify the ta-In addition, the relationship between the IC 50 s of tacrolimus and those of cyclosporine in both cirrhosis pa-crolimus immunosuppressive efficacy, thus influencing allograft survival (28). These antibodies were detected tients and CRF patients were examined. These values are likely to correlate, because the immunosuppressive in the sera of the recipients even before liver transplantation and correlated with the occurrence of allograft re-mechanisms of cyclosporine and tacrolimus are both based on calcineurin inhibition and they actually did so jection after transplantation (28). The anti-FKBP12 autoantibodies have also been detected in the sera of ( Figs. 3a, b ). However, some of the patients obviously deviated from the correlation curves to either the ordinate patients with several autoimmune diseases, including: systemic lupus erythematosus, rheumatoid arthritis, and or horizontal line (patients 1-5 in Fig. 3 ). Accordingly, patient 1 in Figure 3a and patients 4 and 5 in Figure 3b , autoimmune hepatitis (29) . However, no information could be obtained concerning the appearance of these for instance, would be recommended to be treated with tacrolimus, whereas patients 2 and 3 in Figure 3a would kinds of autoantibodies in renal failure patients or hemodialysis patients and thus the influence of these antibod-be recommended to be treated with cyclosporine.
The in vitro response of PBMCs to the suppressive ies on the molecular basis for the different PBMC sensitivity to tacrolimus in CRF and cirrhosis remains to be effects of immunosuppressive drugs correlates with the clinical efficacy of the drugs used in treating renal trans-elucidated.
In conclusion, based on the results of this analysis, plantation (13-16). Although the number of cases examined was not sufficient, a previous study raised the pos-treatment with tacrolimus, rather than cyclosporine, may substantially reduce the burden of graft loss in liver sibility that the response of PBMCs to the effects of immunosuppressive drugs correlated with the clinical transplantation. It is thus possible to reduce the doses of tacrolimus after liver transplantation in highly sensitive efficacy of tacrolimus in liver transplantation (22) . In addition, the current study showed large individual vari-patients, which may decrease the risks of drug side effects, including infection. In contrast, the individual se-ations in the IC 50 values for calcineurin inhibitors in both CRF patients and cirrhosis patients. According to these lection of calcineurin inhibitors in renal transplant recipients is recommended to be carried out based on their in observations, the dose of calcineurin inhibitors should be changed according to the individual sensitivity of vitro PBMC sensitivities to the drugs. PBMCs to the drugs used in treating liver transplanta-ACKNOWLEDGMENTS: This study was supported by a Grant-in-Aid for Scientific Research (Grant number 19590162) tion, as well as in renal transplantation. 
